CABA logo

CABACabaletta Bio Inc

$3.03
$0.015
(0.50%)
Today
Updated: 10:36 AM EDT
Reported EarningsMay 14
Mkt Cap$490.79M
Vol448,988.00
News
all
press releases
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Zacks
News Placeholder
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
Data from a higher dose population is now expected in the second half of 2026.
Stocktwits
News Placeholder
Cabaletta Bio (NASDAQ:CABA) Receives "Overweight" Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued an 'overweight' rating and issued a $30.00 price target on shares of Cabaletta Bio in a research report on Monday...
MarketBeat
News Placeholder
Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 11,001 call options on the stock. This is an increase of 756% compared...
MarketBeat
News Placeholder
Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell
Wall Street Zen downgraded shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
News Placeholder
First Patients Dosed with Cabaletta Bios Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.s (Cabaletta Bio or Cabaletta) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug...
Business Wire
News Placeholder
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One...
MarketBeat
News Placeholder
Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 565.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.